Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 14, Issue 2, Pages 165-172Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2014.874289
Keywords
biomarker; multiple sclerosis; treatment response
Categories
Funding
- German Ministry for Education and Research (BMBF, 'German Competence Network Multiple Sclerosis' (KKNMS), Control-MS) [01GI0917]
- Commission for Clinical Research of the Faculty of Medicine, Technical University Munich, Abirisk
- PML Consortium
- Novartis
- BiogenIdec
- MerckSerono
- Bayer
- Metanomics
- Protagen AG
- 5-prime
- Roche
- Chugai
- Deutsche Forschungsgemeinschaft (DFG)
- Bundesministerium fur Bildung und Forschung (BMBF)
- Hertie Foundation
Ask authors/readers for more resources
Multiple sclerosis (MS) is considered a heterogeneous disease with respect to disease progression and treatment response, which have both remained highly unpredictable. With an increasing number of available disease modifying therapies, strategies for treatment allocation in the individual patient or subgroup of patients has become more important. Therefore biomarkers, which will identify subgroups of MS patients and predict treatment response early in the course of the disease, are urgently needed. Here we review current and emerging biomarkers, as well as study concepts for identification of new biomarkers in MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available